Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on November 3, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyp145
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Amari, M.
Right arrow Articles by Ohuchi, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amari, M.
Right arrow Articles by Ohuchi, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press. All rights reserved

Capecitabine Monotherapy is Efficient and Safe in All Line Settings in Patients with Metastatic and Advanced Breast Cancer

Masakazu Amari, Takanori Ishida, Motohiro Takeda and Noriaki Ohuchi

Division of Surgical Oncology, Tohoku University School of Medicine, Sendai, Japan

For reprints and all correspondence: Noriaki Ohuchi, Division of Surgical Oncology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. E-mail: noriakio{at}mail.tains.tohoku.ac.jp

Received June 12, 2009; accepted September 27, 2009

Objective: Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer. We compared the efficacy and safety of capecitabine monotherapy between 1st, 2nd, 3rd and ≥4th line settings for advanced and metastatic breast cancer pre-treated with/without anthracycline and taxanes.

Methods: Subjects comprised 84 patients with histologically confirmed advanced or metastatic breast cancer and at least one measurable metastatic lesion. We evaluated time to disease progression (TTP), response rate (RR) and clinical benefit rate (CBR) for 1st (n = 17), 2nd (n = 28), 3rd (n = 23) and ≥4th (n = 16) line setting treatments of capecitabine monotherapy.

Results: Median number of cycles of capecitabine monotherapy was 12 cycles in 1st line, 11 cycles in 2nd line, 9 cycles in 3rd line and 11 cycles in ≥4th line. RR and CBR were 23.5% and 58.8% in 1st line, 21.4% and 53.6% in 2nd line, 21.7% and 52.2% in 3rd line, and 18.8% and 50.0% in ≥4th line, respectively. No significant differences in TTP were seen between each line setting (P = 0.843).

Conclusions: Capecitabine monotherapy is effective and well tolerated in all line settings of chemotherapy in patients with metastatic or advanced breast cancer, and is suitable for outpatient therapy.

Key Words: breast cancer • chemotherapy • capecitabine • monotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.